Innate Pharma, Novo Nordisk develop cancer immunotherapy
Executive Summary
Innate Pharma SAS (anticancer immunotherapy based on nonconventional lymphocytes) licensed Novo Nordisk AS exclusive research, development, and commercialization rights to a new class of immunomodulatory antibodies based on a family of receptor targets expressed by natural killer (NK) cells.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Concluded
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice